Literature DB >> 32037535

Identification of HPV genotypes causing cervical precancer using tissue-based genotyping.

Rebecca Venetianer1, Megan A Clarke1, Jacolien van der Marel2, Joseph Tota1, Mark Schiffman1, Samuel Terence Dunn3, Joan Walker3, Rosemary Zuna3, Wim Quint2, Nicolas Wentzensen1.   

Abstract

Identification of high-risk human papillomavirus genotypes causing cervical precancer is crucial for informing HPV vaccine development and efficacy studies, and for determining which types to include in next-generation genotyping assays. Co-occurrence of hrHPV infections is common and complicates carcinogenicity assessment; accurate attribution requires tissue-based genotyping of precancers. We included all women with cervical intraepithelial neoplasia Grade 2 or worse (CIN2+) from the Biopsy Study, an observational study of 690 women enrolled between 2009 and 2012 at the University of Oklahoma. Tissue-based genotyping, including whole tissue sections (WTS) and laser-capture microdissection (LCM), was performed on all precancers with multiple hrHPV infections detected in cytology, totaling over 1,800 HPV genotyping assays. Genotype attribution was compared to hierarchical and proportional hrHPV-type attribution models. Of 276 women with CIN2+, 122 (44.2%) had multiple hrHPV genotypes in cytology. Of 114 women with genotyping data, 94 had one or more hrHPV detected in tissue. Seventy-one women (75.5%) had a single causal hrHPV genotype, while 23 women had multiple hrHPV genotypes causing CIN2+. Ten women had multiple causal infections in a single biopsy, contrary to the previous notion that each lesion is caused by a single type only. While HPV16 was the predominant causal hrHPV genotype using all approaches, the hierarchical model overattributed HPV16, whereas other causal hrHPV genotypes, particularly HPV18 and HPV35, were underattributed. Understanding true causal genotypes is important for the evaluation of vaccine efficacy, to estimate the extent of unmasking, and for type-specific risk assessment in screening and management.
© 2020 UICC.

Entities:  

Keywords:  HPV; cervical cancer; epidemiology; genotype

Year:  2020        PMID: 32037535     DOI: 10.1002/ijc.32919

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management.

Authors:  Jacqueline Mix; Mona Saraiya; Benjamin D Hallowell; Brian Befano; Li C Cheung; Elizabeth R Unger; Julia W Gargano; Lauri E Markowitz; Philip E Castle; Tina Raine-Bennett; Joan Walker; Rosemary Zuna; Mark Schiffman; Nicolas Wentzensen; Julia C Gage
Journal:  J Natl Cancer Inst       Date:  2022-06-13       Impact factor: 11.816

2.  Efficacy of a Coriolus versicolor-Based Vaginal Gel in Women With Human Papillomavirus-Dependent Cervical Lesions: The PALOMA Study.

Authors:  Luis Serrano; Andrés Carlos López; Silvia P González; Santiago Palacios; Damián Dexeus; Cristina Centeno-Mediavilla; Pluvio Coronado; Jesús de la Fuente; José Antonio López; Cristina Vanrell; Javier Cortés
Journal:  J Low Genit Tract Dis       Date:  2021-04-01       Impact factor: 3.842

3.  Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.

Authors:  Fangbin Song; Peisha Yan; Xia Huang; Chun Wang; Hui Du; Xinfeng Qu; Ruifang Wu
Journal:  BMC Cancer       Date:  2022-01-06       Impact factor: 4.430

4.  Clinical Significance of the Interaction between Human Papillomavirus (HPV) Type 16 and Other High-Risk Human Papillomaviruses in Women with Cervical Intraepithelial Neoplasia (CIN) and Invasive Cervical Cancer.

Authors:  Arsenio Spinillo; Mattia Dominoni; Anna C Boschi; Cecilia Sosso; Giacomo Fiandrino; Stefania Cesari; Barbara Gardella
Journal:  J Oncol       Date:  2020-10-26       Impact factor: 4.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.